Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 81131-70-6] Pravastatinsodium

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0165A
Brand:	MCE
CAS:	81131-70-6

Overview

MDL	MFCD00887601
Molecular Weight	446.51
Molecular Formula	C23H35NaO7
SMILES	O[C@@H](C[C@@H](O)CC(O[Na])=O)CC[C@@H]([C@H](C=C1)C)[C@@](C1=C[C@@H](O)C2)([H])[C@H]2OC([C@@H](C)CC)=O

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

[1]Cell Syst. 2018 Apr 25;6(4):424-443.e7.
[2]Front Cell Dev Biol. 2022 Mar 3;10:806081.
[3]Front Cell Dev Biol. 2020 May 28;8:404.
[4]Research Square Preprint. 2022 Feb.

Summary

Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC ₅₀ of 5.6 μM.

IC50 & Target

HMG-CoA reductase ^[1] .

In Vitro

Pravastatin (CS-514) is a member of the drug class of statins, used in combination with diet, exercise, and weight-loss for lowering cholesterol and preventing cardiovascular disease ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00456365	University of Colorado, Denver\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Polycystic Kidney, Autosomal Dominant	November 2006	Phase 3
NCT04190433	Mayo Clinic	Lymphoma	September 1, 2020	Phase 2
NCT00829309	Teva Pharmaceuticals USA	Healthy	March 2005	Phase 1
NCT02992548	Dong-A University	Chronic Kidney Disease	September 2015	Phase 4
NCT00433498	University College, London	Lung Cancer	January 2007	Phase 3
NCT00305201	Pontificia Universidad Catolica de Chile\|Bristol-Myers Squibb	Kawasaki Disease	April 2006	Phase 2
NCT01057654	University Hospital, Bonn	Hypercholesterolemia\|Hyperlipoproteinemia	January 1996	Phase 3
NCT00571194	Arkansas Children´s Hospital Research Institute	End Stage Renal Disease	September 2007	Phase 1
NCT00005010	National Institute of Allergy and Infectious Diseases (NIAID)	End-Stage Renal Disease\|Chronic Allograft Nephropathy		Phase 3
NCT01441908	MaiHealth Inc	Dyslipidemia	June 2011	Not Applicable
NCT01903694	Centre Hospitalier Universitaire Dijon	Child-Pugh A Hepatocellular Carcinoma	March 2010	Phase 3
NCT00166036	Emory University	Diabetes Mellitus\|Metabolic Syndrome X\|Hypercholesterolemia	September 2004	Phase 2
NCT00688922	Osaka Acute Coronary Insufficiency Study Group	Acute Myocardial Infarction	July 2008	Phase 4
NCT03801733	Akebia Therapeutics	Drug Interaction Potentiation	June 17, 2018	Phase 1
NCT00631189	AstraZeneca	Type IIa and IIb Hypercholesterolaemia	October 2007	Phase 4
NCT00330980	University of California, San Diego\|National Heart, Lung, and Blood Institute (NHLBI)	Dyslipidemias	April 2000	Phase 4
NCT01557075	Yonsei University	Drug-eluting Stent (DES)	July 2010	Phase 4
NCT01845428	University of North Carolina, Chapel Hill\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Nephrotic Syndrome\|Hyperlipidemia	May 2012	Phase 1
NCT00701285	JW Pharmaceutical	Chronic Heart Failure	July 2008	Phase 4
NCT03944512	The George Washington University Biostatistics Center\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|National Heart, Lung, and Blood Institute (NHLBI)	Preeclampsia\|Obstetric Labor Complications\|Hypertension in Pregnancy	July 17, 2019	Phase 3
NCT00303277	Seattle Institute for Biomedical and Clinical Research	Alzheimer´s Disease\|Aging	August 2002	Phase 4
NCT00697203	Hoffmann-La Roche	Dyslipidemia	July 2005	Phase 2
NCT00384618	Amsterdam UMC, location VUmc\|Medical Research Foundation, The Netherlands\|Bristol-Myers Squibb	Chronic Kidney Disease	May 2001	Phase 4
NCT00916747	Boston Children´s Hospital\|Schering-Plough\|Merck Sharp & Dohme LLC\|Eiger BioPharmaceuticals	Progeria	August 2009	Phase 2
NCT00382460	Bristol-Myers Squibb	Actue Coronary Syndromes	November 2000	Phase 4
NCT00982189	Hennepin Healthcare Research Institute\|American Heart Association	HIV Infection\|Cardiovascular Disease Risk	September 2009	Not Applicable
NCT00665717	Radboud University Medical Center\|Merck Sharp & Dohme LLC	HIV Infections	May 2008	Phase 1
NCT00221104	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan\|Ministry of Health, Labour and Welfare, Japan\|Hiroshima University	Ischemic Stroke	March 1, 2004	Phase 3
NCT00054938	Brigham and Women´s Hospital\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Systemic Lupus Erythematosus\|Lupus	March 2003	Phase 2
NCT01146106	Dr. Reddy´s Laboratories Limited	Healthy	December 2002	Phase 1
NCT04284657	University of Southern California	Autosomal Dominant Polycystic Kidney Disease	January 30, 2019	Phase 2
NCT02518516	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Hypercholesterolemia	January 2011
NCT02079974	Dr. Robert F. Casper\|Toronto Centre for Advanced Reproductive Technology	Endometriosis	July 2014	Not Applicable
NCT05107063	Daiichi Sankyo, Inc.\|Daiichi Sankyo Korea Co., Ltd.	Dyslipidemia Associated With Type II Diabetes Mellitus	January 20, 2016
NCT01717586	The University of Texas Medical Branch, Galveston\|University of Pittsburgh\|Northwestern University\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Preeclampsia	August 2012	Phase 1
NCT01816997	Taipei Veterans General Hospital, Taiwan	Diabetes	January 2012	Phase 4
NCT00107523	Fred Hutchinson Cancer Center	Leukemia	January 2005	Phase 1
NCT02360826	Children´s Mercy Hospital Kansas City\|American Heart Association	Drug Distribution	June 17, 2014	Phase 1
NCT00467831	National Human Genome Research Institute (NHGRI)\|National Institutes of Health Clinical Center (CC)	Hermansky-Pudlak Syndrome (HPS)\|Pulmonary Fibrosis\|Oculocutaneous Albinism\|Platelet Storage Pool Deficiency\|Metabolic Disease	April 2007	Phase 1\|Phase 2
NCT00654537	AstraZeneca	Hypercholesterolemia	April 2001	Phase 3
NCT00459745	Shionogi\|Integrium\|Shionogi Inc.	Combined Hyperlipidemia	April 2007	Phase 3
NCT02621957	Genentech, Inc.	Breast Cancer	December 2015	Phase 1
NCT00702130	University of Thessaly	Ventilator Associated Pneumonia	June 2008	Early Phase 1
NCT00834379	Teva Pharmaceuticals USA	Healthy	September 2000	Phase 1
NCT00830258	Teva Pharmaceuticals USA	Healthy	April 2005	Phase 1
NCT04425902	ViiV Healthcare	HIV Infections	December 16, 2020	Phase 1
NCT00639223	University of Pennsylvania\|Chestnut Hill Health System	Hypercholesterolemia\|Statin-Associated Myopathy	January 2008	Phase 2
NCT01146093	Dr. Reddy´s Laboratories Limited	Healthy	November 2002	Phase 1
NCT03219372	Cedars-Sinai Medical Center\|National Institutes of Health (NIH)\|National Cancer Institute (NCI)	Hepatocellular Carcinoma\|Liver Cirrhoses	September 27, 2018	Phase 2
NCT02456844	Bristol-Myers Squibb	Rheumatoid Arthritis	May 2015	Phase 1
NCT03456102	Johns Hopkins University	Tuberculosis	March 9, 2020	Phase 2
NCT01301066	Kowa Research Institute, Inc.\|Kowa Pharmaceuticals America, Inc.\|Eli Lilly and Company	Dyslipidemia	December 2010	Phase 4
NCT02229773	Boehringer Ingelheim	Healthy	January 2000	Phase 1
NCT00688896	Akros Pharma Inc.	Type II Hyperlipidemia	June 2002	Phase 2
NCT01831232	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Refractory Anemia With Excess Blasts\|Untreated Adult Acute Myeloid Leukemia	May 2013	Not Applicable
NCT01342887	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	April 2011	Phase 1\|Phase 2
NCT01857921	Yonsei University	Coronary Artery	December 2010	Not Applicable
NCT01268202	Gustave Roussy, Cancer Campus, Grand Paris\|Ministry of Health, France	Fibrosis	December 17, 2010	Phase 2
NCT03273413	University of Colorado, Denver	ADPKD\|Autosomal Dominant Polycystic Kidney	August 31, 2017	Phase 4
NCT00650221	Mylan Pharmaceuticals Inc\|Genpharm ULC\|MylanPharma	Therapeutic Equivalency	June 2003	Phase 1
NCT01254461	AstraZeneca	Drug Interaction	February 2011	Phase 1
NCT00006412	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Lipodystrophy		Phase 3
NCT00549926	Yokohama City University Medical Center	Coronary Disease\|Hypercholesterolemia	October 2007	Phase 4
NCT00599625	University of Virginia\|American College of Gastroenterology	Crohn´s Disease	October 2004	Not Applicable
NCT00227500	Kirby Institute\|The University of New South Wales\|National Heart, Lung, and Blood Institute (NHLBI)\|Garvan Institute of Medical Research\|St Vincent´s Hospital, Sydney	HIV Infections\|Lipid Metabolism\|Glucose Metabolism\|Metabolic Abnormality\|Lipodystrophy\|Cardiovascular Disease	July 2001	Phase 4
NCT03648970	Universitas Airlangga	Pre-Eclampsia	March 1, 2018	Phase 2
NCT02266485	Boehringer Ingelheim	Healthy	July 1998	Phase 1
NCT00039663	National Institutes of Health Clinical Center (CC)	HIV Infections	May 2002	Phase 1
NCT03073018	University Medical Center Groningen\|Dutch Kidney Foundation\|Netherlands Heart Foundation	Microalbuminuria\|Cardiovascular Diseases\|Renal Disease	April 1998	Phase 3
NCT00000542	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Disease\|Diabetes Mellitus\|Heart Diseases\|Hypercholesterolemia\|Hypertension\|Myocardial Infarction\|Myocardial Ischemia\|Heart Failure	August 1993	Phase 3
NCT04719481	Peking University Third Hospital	Postmenopausal Osteoporosis	November 2021	Phase 4
NCT03882177	National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis\|Pulmonary Tuberculosis	February 21, 2020	Phase 2
NCT00362206	Solvay Pharmaceuticals	Hyperlipidemia	September 2006	Phase 3
NCT01958489	Eli Lilly and Company	Healthy Volunteers	October 2013	Phase 1
NCT02431013	Ajou University School of Medicine	Dyslipidemias\|Peripheral Artery Disease	April 2015	Phase 1
NCT00000941	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 1
NCT02518503	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Diabetes Mellitus, Type 2\|Cardiovascular Disease	July 2012
NCT00000461	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Disease\|Heart Diseases\|Myocardial Ischemia	December 1986	Phase 2
NCT01856374	Yonsei University	Multi-vessel Diseases, Angina	August 2011	Phase 4
NCT01075555	Federation Francophone de Cancerologie Digestive\|Centre Hospitalier Universitaire Dijon	Liver Cancer	February 2010	Phase 3
NCT00738296	Hospital Universitario 12 de Octubre\|Merck Sharp & Dohme LLC\|Hospital Regional 1o de Octubre	Cardiovascular Diseases	April 2005	Phase 4
NCT01602913	GlaxoSmithKline	Depression, Postpartum	December 2011
NCT03510715	Sanofi\|Regeneron Pharmaceuticals	Hypercholesterolemia	August 31, 2018	Phase 3
NCT00731016	Assistance Publique Hopitaux De Marseille	Hutchinson-Gilford Progeria Syndrome	October 2008	Phase 2
NCT00214604	AstraZeneca	Hyperlipoproteinemia Type III	February 2005	Phase 3
NCT00117494	French National Agency for Research on AIDS and Viral Hepatitis	Hyperlipidemia\|HIV Infections	October 2005	Phase 4
NCT00840177	Southwest Oncology Group\|National Cancer Institute (NCI)	Leukemia	August 2009	Phase 2
NCT00177580	University of Pittsburgh\|Stanley Medical Research Institute	Schizophrenia\|Schizoaffective Disorder	July 2003	Phase 4
NCT04640571	University of Maryland, Baltimore	Bile Salt Export Pump (BSEP) Transporter\|Polysorbate 80	April 1, 2021	Phase 4
NCT00257686	Kowa Research Europe	Hypercholesterolemia or Combined Dyslipidemia	September 2005	Phase 3
NCT02754739	Samsung Medical Center\|Daiichi Sankyo Korea Co., Ltd.	Diabetes Mellitus\|Prediabetic State	April 15, 2014	Phase 4
NCT01173939	Positive Trial Group	Hypercholesterolemia\|Type 2 Diabetes\|Hypertension	July 2010	Not Applicable
NCT04356209	Institut du Cancer de Montpellier - Val d´Aurelle	Breast Cancer	September 28, 2020	Phase 2
NCT01082588	Massachusetts General Hospital\|Stanley Medical Research Institute\|North Suffolk Mental Health Association	Schizophrenia\|Schizoaffective Disorders\|Schizophreniform Disorders	June 2010	Phase 4
NCT01515813	AIDS Clinical Trials Group\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV-1 Infection	November 2011	Phase 2
NCT00200655	Nantes University Hospital	Relapsing-remitting Multiple Sclerosis	December 2004	Phase 3
NCT00879034	Boston Children´s Hospital\|Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Schering-Plough	Progeria\|Hutchinson-Gilford Syndrome	March 2009	Phase 2
NCT03510884	Sanofi\|Regeneron Pharmaceuticals	Hypercholesterolaemia	May 31, 2018	Phase 3
NCT01788254	Matthias Schwab\|University Hospital Tuebingen	Genotype-related Drug Metabolism	January 2012	Phase 1
NCT01845194	Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH	Drug Biotransformation\|Membrane Transport	December 2009	Phase 1
NCT01502904	Yonsei University	Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension	July 2010	Phase 4
NCT02841774	Matthew Feinstein\|Northwestern University	HIV Infection\|Coronary Heart Disease	November 2016	Phase 2
NCT00221754	University Hospital, Bordeaux\|Ministry of Health, France	HIV Infection\|Hypercholesterolemia	March 2003	Phase 2
NCT00529178	Bristol-Myers Squibb	Hypercholesterolemia	December 2002	Phase 4
NCT00132717	Organon and Co	Hypercholesterolemia	January 1, 2005	Phase 3
NCT04608344	Gilead Sciences\|Galapagos NV	Rheumatoid Arthritis	November 4, 2020	Phase 1
NCT00738972	Fundación Lindavista del Corazón AC	Hypertension	January 2008	Phase 3
NCT00005117	National Center for Research Resources (NCRR)	Heart Diseases		Not Applicable
NCT00017758	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|HIV Seronegativity\|Lipodystrophy		Phase 1
NCT05524246	Children´s Hospital Medical Center, Cincinnati	Hematopoietic Stem Cell Transplant (HSCT)\|Endothelial Injury	November 2022	Phase 1
NCT02484261	Reuven Schore\|Millennium Pharmaceuticals, Inc.\|Hyundai Hope On Wheels\|Children´s National Research Institute	Leukemia	May 2015	Phase 1
NCT00843661	Ospedale di Circolo - Fondazione Macchi\|Merck Sharp & Dohme LLC	HIV\|Hyperlipidemia\|HIV Infections	March 2009	Phase 4
NCT00000539	National Heart, Lung, and Blood Institute (NHLBI)	Arterial Occlusive Diseases\|Cardiovascular Diseases\|Heart Diseases\|Vascular Diseases\|Diabetes Mellitus	September 1992	Phase 3
NCT00755352	Daiichi Sankyo, Inc.	Hypercholesterolemia	November 2002	Phase 4
NCT01418729	Hospital Donostia\|INSTITUTO BIODONOSTIA	Advanced Hepatocarcinoma	September 2011	Phase 2
NCT00834847	Teva Pharmaceuticals USA	Healthy	August 2000	Phase 1
NCT03131973	Bristol-Myers Squibb	Rheumatoid Arthritis	May 13, 2017	Phase 1
NCT00380939	Pfizer	Coronary Arteriosclerosis	April 1999	Phase 4
NCT01038154	Hospital Donostia	Esophageal Cancer\|Stomach Cancer	November 2009	Phase 4
NCT01256476	Kowa Research Institute, Inc.	Primary Dyslipidemia\|Mixed Dyslipidemia	October 2010	Phase 4
NCT02155530	Yonsei University	Coronary Artery Disease	June 2014	Not Applicable
NCT01857843	Yonsei University	Acute Coronary Syndrome	November 2009	Phase 4
NCT02871687	Brigham and Women´s Hospital	Healthy Subjects	April 2016	Phase 1
NCT00630734	University of Colorado, Denver\|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA	HIV Infections\|Hyperlipidemia	February 2008	Phase 4
NCT01497483	University of California, San Francisco\|National Institute of General Medical Sciences (NIGMS)	Healthy	December 2011	Phase 1
NCT01872845	Yonsei University	Coronary Artery Occlusive Disease	June 12, 2013	Not Applicable
NCT01357486	University Hospital, Bordeaux\|Federation Francophone de Cancerologie Digestive\|UNICANCER	Hepatocellular Carcinoma\|CHILD B	November 14, 2011	Phase 2
NCT02547402	Complexa, Inc.	Acute Kidney Injury	December 2015	Phase 1
NCT00648544	Mylan Pharmaceuticals Inc\|Genpharm ULC\|MylanPharma	Therapeutic Equivalency	July 2003	Phase 1

Appearance

Solid

Source

Penicillium Citrinum

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 223.96 mM ; Need ultrasonic)

H ₂ O : ≥ 50 mg/mL ( 111.98 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2396 mL	11.1980 mL	22.3959 mL
5 mM	0.4479 mL	2.2396 mL	4.4792 mL
10 mM	0.2240 mL	1.1198 mL	2.2396 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (223.96 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] McTavish D, et al. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89.

Synonyms

1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, sodium salt (1:1), (βR,δR,1S,2S,6S,8S,8aR)-

1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S-[1α(βS*,δS*),2α,6α,8β(R*),8aα]]-

1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)-

CS 514

SQ 31000

Epastatin sodium

Pravastatin sodium

Mevalotin

Pravachol

Sodium pravastatin

Pravastatin sodium salt

Pravacol

Vasten

Lipostat

Selektine

Elisor

Pravasine

Liprevil

Prava

Pravaselect

Pravasin

Selipran

Selectin

Lipidal

Oliprevin

3β-Hydroxycompactin sodium salt

Eptastatin sodium

Mevan

Pravator

Pravastin

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart